Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Mar 10, 2023
Open Peer Review Period: Mar 8, 2023 - Mar 22, 2023
Date Accepted: Jun 15, 2023
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Survival and Trends in Annualized Hazard Function by Age at Diagnosis Among Chinese Breast Cancer Patients Aged ≤40 Years: Case Analysis Study

Wang J, Luo T, Xiang Zz, Zeng Yy, Yang T, Wei Xy, Yu S, Dai Zl, Xu Ny, Tan Cf, Liu L

Survival and Trends in Annualized Hazard Function by Age at Diagnosis Among Chinese Breast Cancer Patients Aged ≤40 Years: Case Analysis Study

JMIR Public Health Surveill 2023;9:e47110

DOI: 10.2196/47110

PMID: 37463020

PMCID: 10394600

Survival and trends of annualized hazard function by age at diagnosis among Chinese breast cancer patients aged ≤ 40 years: a case analysis study

  • Jun Wang; 
  • Ting Luo; 
  • Zhong-zheng Xiang; 
  • Yuan-yuan Zeng; 
  • Tian Yang; 
  • Xiao-yuan Wei; 
  • Siting Yu; 
  • Ze-lei Dai; 
  • Ning-yue Xu; 
  • Chen-feng Tan; 
  • Lei Liu

ABSTRACT

Background:

Young breast cancer patients are more likely to develop aggressive tumor characteristics and worse prognosis than older women, and have distinct epidemiology and prognosis in different races. However, rare studies have evaluated the clinical biological features and relapse patterns according to different age strata of young women in Asia

Objective:

To explore the survival difference and hazard function of young breast cancer (BC) by age in Chinese patients.

Methods:

The patients were enrolled from West China hospital, Sichuan University. Chi-squared test, Kaplane-Meier analysis, log-rank test, cox multivariate hazards regression model, and hazard function were applied for data analyzing.

Results:

We included 1,950 young BC patients diagnosed between 2008 and 2019. Patients aged ≤ 25, 26-30, 31-35, and 36-40 years accounted for 2.8%, 11.7%, 27.6%, and 57.8%, respectively. The diagnosis of young BC significantly increased from 2008 to 2019. Five-year locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), breast cancer-specific survival (BCSS), and overall survival (OS) for the entire population were 98.3%, 93.4%, 94.3%, and 93.9%, respectively. Patients aged ≤25 years had significantly poorer 5-year LRFS (P<.001), 5-year DMFS (P<.001), 5-year BCSS (P=.04), and 5-year OS (P=.04) than those aged 31-35, 26-30, and 36-40 years. The annualized hazard function for recurrence, metastasis, and BC mortality in all patients and different age strata showed significantly different trends, especially for BC mortality.

Conclusions:

The annual diagnosis of young BC seemed to increase in Chinese patients, and distinct age-strata of young BC patients didn’t differ for survival outcome and failure patterns.


 Citation

Please cite as:

Wang J, Luo T, Xiang Zz, Zeng Yy, Yang T, Wei Xy, Yu S, Dai Zl, Xu Ny, Tan Cf, Liu L

Survival and Trends in Annualized Hazard Function by Age at Diagnosis Among Chinese Breast Cancer Patients Aged ≤40 Years: Case Analysis Study

JMIR Public Health Surveill 2023;9:e47110

DOI: 10.2196/47110

PMID: 37463020

PMCID: 10394600

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.